Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to update the listing to include reference to the tetraphosphate salt of pyronaridine in the formulation description instead of the medicine name. - to remove the weight restriction, recognizing that use should be in accordance with recommendations in WHO guidelines for malaria treatment.